-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical’s Moxifloxacin Hydrochloride Tablets Approved
Category:
发布时间：2022-01-24
【概要描述】
On January 11, moxifloxacin hydrochloride tablets (0.4 g) developed by Shijiazhuang Sihua Pharmaceutical Co., Ltd. were granted a drug registration certificate by the National Medical Products Administration and are deemed to have passed the evaluation of quality and therapeutic equivalence for generic drugs.
At the start of the new year, Shijiazhuang Sihua Pharmaceutical Co., Ltd. has once again announced encouraging news in its research and development efforts. On January 11, the company’s moxifloxacin hydrochloride tablets (0.4 g) received a Drug Registration Certificate from the National Medical Products Administration, which also signifies that the product has been deemed to have passed the evaluation of quality and therapeutic equivalence for generic drugs.
Previously, Shijiazhuang Sihua Pharmaceutical’s moxifloxacin hydrochloride and sodium chloride injection was approved by the National Medical Products Administration in 2020 and passed the evaluation of quality and therapeutic equivalence for generic drugs. The recent approval of moxifloxacin hydrochloride tablets further strengthens the development of a comprehensive moxifloxacin product portfolio.
According to the introduction, moxifloxacin is a fourth-generation quinolone antibacterial agent and a new-generation antibiotic with a broad antimicrobial spectrum, primarily used to treat various bacterial infections, including pneumonia, pulmonary tuberculosis, endocarditis, conjunctivitis (pink eye), and respiratory tract infections.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091